Recommendations
The Council for Choices in Health Care has issued the following recommendations:
19.12.2019 Tisagenlecleucel therapy (Kymriah) in the treatment of diffuse large B-cell lymphoma
13.12.2019 Cemiplimab (Libtayo) for the treatment of cutaneous advanced squamous cell carcinoma
4.12.2019 Surgery of a lumbar disc hernia and subsequent rehabilitation
20.9.2019 Criteria for continued treatment with nusinersen
12.6.2019 Durvalumab for treating non-small-cell lung cancer after chemoradiation
13.3.2019 Nivolumab, atezolizumab and pembrolizumab in treatment of non-small-cell lung cancer
13.3.2019 Tisagenlecleucel (Kymriah®) in the treatment of B-cell acute lymphoblastic leukaemia
5.2.2019 Pertuzumab used as adjuvant treatment for HER2 positive breast cancer
18.12.2018 Obinutuzumab as first-line treatment for follicular lymphoma
4.9.2018 Atetzolizumab, nivolumab and pembrolizumab in the treatment of advanced or metastatic bladder cancer
9.10.2018 Benralizumab, mepolizumab and in the treatment of extremely severe eosinophilic asthma
1.11.2018 Biopsychosocial rehabilitation in prolonged or recurrent back pain
1.11.2018 Psychotherapy and other psychosocial interventions in the treatment and rehabilitation of mental disorders and substance use disorders
12.6.2018 Sebelipase alfa in the treatment of lysosomal acid lipase deficiency
15.3.2018 Nusinersen in treating Spinal Muscular Atropy (SMA) – Approved at the meeting of COHERE on 15 march 2018
8.2.2017 Knee degeneration treatment by keyhole surgery
30.8.2016 Rehabilitation after hip fracture surgery
30.8.2016 Implant-retained total prosthesis for the treatment of edentulous mandible
10.12.2015 Treatment of age-related macular degeneration with intravitreal bevacizumab is included in the publicly funded health service range of Finland
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: "Psychosocial interventions in drug dependence treatment and rehabilitation". Approved by the meeting of COHERE on 6 october 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: "The use of brolucizumab in the treatment of neovascular age-related macular degeneration". Approved by the meeting of COHERE on 1 september 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: " The use of cerliponase alfa in the treatment of neuronal ceroid lipofuscinosis type 2 (cln2)". Approved by the meeting of COHERE on 1 september 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: " The use of avelumab as first-line treatment for urothelial" . Approved by the meeting of COHERE on 1 september 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: " The use of durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small-cell lung cancer". Approved by the meeting of COHERE on 17 june 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: " Combination therapy with atezolizumab, etoposide and carboplatin in the first-line treatment of advanced small-cell lung cancer". Approved by the meeting of COHERE on 17 june 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: " The use of eculizumab in the treatment of neuromyelitis optica spectrum disorder (nmosd)". Approved by the meeting of COHERE on 5 may 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: "Luspatercept in the treatment of red-blood-cell transfusion-dependent anaemia associated with myelodysplastic syndrome". Approved by the meeting of COHERE on 5 may 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: "The use of zynteglo in the treatment of beta-thalassaemia". Approved by the meeting of COHERE on 5 may 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: "Treating chronic symptoms in the lumbar spine with spinal fusion surgery and post-operative rehabilitation". Approved by the meeting of COHERE on 23 march 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: "Decreasing the risk of disease caused by poor oral hygiene in high-risk patients with support for self-management of oral health and lifestyle counselling". Approved by the meeting of COHERE on 23 march 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: "Luspatercept in the treatment of red-blood-cell transfusion-dependent anaemia among adults with beta thalassaemia". Approved by the meeting of COHERE on 23 march 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: "Luspatercept in the treatment of red-blood-cell transfusion-dependent anaemia associated with myelodysplastic syndrome". Approved by the meeting of COHERE on 23 march 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: "Factors supporting lifestyle changes when using methods for providing lifestyle counselling and supporting self-management of health to reduce the risk of diseases caused by an unhealthy diet and insufficient physical activity". Approved by the meeting of COHERE on 25 september 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: "Screening for severe combined immunodeficiency (SCID) using a heel prick test for newborn babies". Approved by the meeting of COHERE on 25 september 2021.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
"Factors supporting lifestyle changes when using methods for providing lifestyle counselling and supporting self-management of health to reduce the risk of smoking-related diseases". Approved by the meeting of COHERE on 11 june 2020.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Tisagenlecleucel therapy (Kymriah) in the treatment of diffuse large B-cell lymphoma.''
Approved by the meeting of COHERE on 12 december 2019.
Recommendation (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Axicabtagene ciloleucel (Yescarta) in the treatment of refractory or relapsed diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL).''
Approved by the meeting of COHERE on 12 december 2019.
Recommendation (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Cemiplimab (Libtayo) for the treatment of cutaneous advanced squamous cell carcinoma.''
Approved by the meeting of COHERE on 12 december 2019.
Recommendation (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Surgery of a lumbar disc hernia and subsequent rehabilitation.''
Approved by the meeting of COHERE on 29 october 2019.
Recommendation (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Recommendation on combination treatment with nivolumab and ipilimumab as first-line treatment for advanced renal clear cell carcinoma.''
Approved by the meeting of COHERE on 29 october 2019.
Recommendation (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation:''Daratumumab in combination (D-VMP) and as maintenance therapy of newly diagnosed multiple myeloma.''
Approved by the meeting of COHERE on 4 september 2019.
Recommendation (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Durvalumab for treating non-small-cell lung cancer after chemoradiation.''
Approved by the meeting of COHERE on 12 june 2019.
Recommendation (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Nivolumab, atezolizumab and pembrolizumab in treatment of non-small-cell lung cancer.''
Approved by the meeting of COHERE on 13 march 2019.
Recommendation (nivolumab)
Recommendation (atezolizumab)
Recommendation (pembrolizumab first-line)
Recommendation (pembrolizumab second-line)
Background memo (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Tisagenlecleucel (Kymriah®) in the treatment of B-cell acute lymphoblastic leukaemia.''
Approved by the meeting of COHERE on 13 march 2019.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Pertuzumab used as adjuvant treatment for HER2 positive breast cancer''.
Approved by the meeting of COHERE on 5 february 2019
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Obinutuzumab as first-line treatment for follicular lymphoma''.
Approved by the meeting of COHERE on 18 december 2018.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Atetzolizumab, nivolumab and pembrolizumab in the treatment of advanced or metastatic bladder cancer''.
Approved by the meeting of COHERE on 4 september 2018.
Recommendation - atetzolizumabi
Recommendation - pembrolizumab
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Recommendation: ''Benralizumab, mepolizumab and reslizumab in the treatment of extremely severe eosinophilic asthma''
Approved by the meeting of COHERE on 9 October 2018.
Background memo (In Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Approved by the meeting of COHERE on 1 November 2018
Biopsychosocial rehabilitation is included in the range of public health services if back pain prolongs despite treatment at the initial phase of the problem, or if patients suffer back pain repeatedly and their functional capacity and work ability are compromised due to the pain.
Rehabilitative measures to maintain and improve patients' functional capacity and work ability are planned within six weeks from the beginning of the symptoms, as part of the patients’ other treatment and taking account of the patient's whole life situation.
Background memo (In Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Approved by the meeting of COHERE on 1 November 2018
Psychotherapy and other psychosocial interventions in the treatment and rehabilitation of mental disorders and substance use disorders
Psychotherapies and psychosocial interventions proven effective are included in the range of public health services in the treatment and rehabilitation of mental disorders and substance use disorders. The methods are part of a goal-oriented approach in all phases of the treatment.
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Sebelipase alfa in the treatment of lysosomal acid lipase deficiency.
Approved at the meeting of COHERE on 12 June 2018.
Sebelipase alfa treatment would be included in the national range of services for treating lysosomal acid lipase deficiency in infantile-onset patients if its price were significantly lower.
Background memo Perustelumuistio (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Nusinersen in treating Spinal Muscular Atropy (SMA) - Approved at the meeting of COHERE on 15 March 2018.
Background memo Perustelumuistio (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
The Council for Choices in Health Care in Finland recommends that knee degeneration treatment by keyhole surgery not included in publicly funded healthcare services in Finland
Background memo Perustelumuistio (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
The Council for Choices in Health Care in Finland recommends the treatment of wet age-related macular degeneration (AMD) with bevacizumab injection in the eye to be included in the publicly funded service choices in health care in Finland.
Background memo Taustayhteenveto (in Finnish)
Link to Fimea’s report “Biologiset lääkkeet silmänpohjan kostean ikärappeuman hoidossa” (2015) ; link to the summary (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
The treatment of an edentulous mandible with a total prosthesis retained with two implants belongs to the publicly funded service choices in health care in Finland when the patient's ability to eat, speak or engage in other social interaction is impaired due to the instability or unsuitability of a total mandibular prosthesis.
Background memo Taustayhteenveto (in Finnish)
Recommendation by the Council for Choices in Health Care in Finland (COHERE Finland)
Multi-professional, goal-oriented rehabilitation that activates the patient after hip fracture surgery is part of the range of health services financed from public funds in Finland.
Backround memo Taustayhteenveto (in Finnish)
